Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cis-cyclo(L-Phe-L-Pro)
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
cis-cyclo(L-Phe-L-Pro) is a cyclic dipeptide (2,5-diketopiperazine) composed of L-phenylalanine and L-proline in the cis configuration. It is a secondary metabolite produced by various microorganisms including Lactobacillus plantarum and certain fungi. This compound exhibits broad-spectrum antibacterial and antifungal activities, with demonstrated efficacy against multidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus raffinosus, and also shows activity against influenza A (H3N2) virus[2][5]. Mechanistically, it interferes with bacterial quorum sensing systems—specifically N-acylhomoserine lactone-mediated signaling—and inhibits biofilm formation by affecting the expression of genes related to quorum sensing and polysaccharide intercellular adhesion[1][4]. Additionally, it displays free radical scavenging properties in vitro. Its precise molecular mechanism remains incompletely characterized but involves modulation of microbial communication pathways.
- Other names
- cyclo(L-Phe-L-Pro)Cyclo(-Phe-Pro)Cyclo-L-phenylalanyl-L-proline(3S,8aS)-3-Benzylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione
02
Targets
N-acyl homoserine lactone-dependent LuxR-type quorum sensing receptor
Beyond the preview
Go deeper on cis-cyclo(L-Phe-L-Pro).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cis-cyclo(L-Phe-L-Pro).